Open-label follow-on study evaluating the efficacy, safety, and quality of life with extended daily oral immunotherapy in children with peanut allergy.
Authors
Fernandez-Rivas, MontserratVereda, Andrea
Vickery, Brian P
Sharma, Vibha
Nilsson, Caroline
Muraro, Antonella
Hourihane, Jonathan O'B
DunnGalvin, Audrey
du Toit, George
Blumchen, Katharina
Beyer, Kirsten
Smith, Alex
Ryan, Robert
Adelman, Daniel C
Jones, Stacie M
Issue Date
2021-09-24Keywords
desensitizationfood allergy
oral immunotherapy
peanut allergy
QUALITY OF LIFE
Metadata
Show full item recordJournal
AllergyDOI
10.1111/all.15027PubMed ID
34320250Item Type
ArticleOther
Language
enEISSN
1398-9995ae974a485f413a2113503eed53cd6c53
10.1111/all.15027
Scopus Count
Collections
The following license files are associated with this item:
- Creative Commons
Except where otherwise noted, this item's license is described as © 2021 Aimmune Therapeutics. Allergy published by European Academy of Allergy and Clinical Immunology and John Wiley & Sons Ltd.
Related articles
- Continuous and Daily Oral Immunotherapy for Peanut Allergy: Results from a 2-Year Open-Label Follow-On Study.
- Authors: Vickery BP, Vereda A, Nilsson C, du Toit G, Shreffler WG, Burks AW, Jones SM, Fernández-Rivas M, Blümchen K, O'B Hourihane J, Beyer K, Anagnostou A, Assa'ad AH, Ben-Shoshan M, Bird JA, Carr TF, Carr WW, Casale TB, Chong HJ, Ciaccio CE, Dorsey MJ, Fineman SM, Fritz SB, Greiner AN, Greos LS, Hampel FC Jr, Ibáñez MD, Jeong DK, Johnston DT, Kachru R, Kim EH, Lanser BJ, Leonard SA, Maier MC, Mansfield LE, Muraro A, Ohayon JA, Oude Elberink JNG, Petroni DH, Pongracic JA, Portnoy JM, Rachid R, Rupp NT, Sanders GM, Sharma HP, Sharma V, Sher ER, Sher L, Sindher SB, Siri D, Spergel JM, Sprikkelman AB, Sussman GL, Tsoumani M, Varshney P, Vitalpur G, Wang J, Yang WH, Zubeldia JM, Smith A, Ryan R, Adelman DC
- Issue date: 2021 May
- Post hoc analysis examining symptom severity reduction and symptom absence during food challenges in individuals who underwent oral immunotherapy for peanut allergy: results from three trials.
- Authors: Blumchen K, Kleinheinz A, Klimek L, Beyer K, Anagnostou A, Vogelberg C, Butovas S, Ryan R, Norval D, Zeitler S, Du Toit G
- Issue date: 2023 Mar 13
- Safety of peanut (Arachis hypogaea) allergen powder-dnfp in children and teenagers with peanut allergy: Pooled summary of phase 3 and extension trials.
- Authors: Brown KR, Baker J, Vereda A, Beyer K, Burks AW, du Toit G, O'B Hourihane J, Jones SM, Norval D, Dana A, Shreffler W, Vickery BP, Casale T, Skeel B, Adelman D
- Issue date: 2022 Jun
- Efficacy and safety of oral immunotherapy with AR101 in European children with a peanut allergy (ARTEMIS): a multicentre, double-blind, randomised, placebo-controlled phase 3 trial.
- Authors: O'B Hourihane J, Beyer K, Abbas A, Fernández-Rivas M, Turner PJ, Blumchen K, Nilsson C, Ibáñez MD, Deschildre A, Muraro A, Sharma V, Erlewyn-Lajeunesse M, Zubeldia JM, De Blay F, Sauvage CD, Byrne A, Chapman J, Boralevi F, DunnGalvin A, O'Neill C, Norval D, Vereda A, Skeel B, Adelman DC, du Toit G
- Issue date: 2020 Oct
- Peanut (Arachis hypogaea) allergen powder-dnfp for the mitigation of allergic reactions to peanuts in children and adolescents.
- Authors: Casale TB, Irani AM
- Issue date: 2023 Mar